New plasmid-mediated aminoglycoside 6′-N-acetyltransferase, AAC(6′)-Ian, and ESBL, TLA-3, from a Serratia marcescens clinical isolate

Abstract

Abstract Objectives Enterobacteriaceae clinical isolates showing amikacin resistance (MIC 64 to >256 mg/L) in the absence of 16S rRNA methyltransferase (MTase) genes were found. The aim of this study was to clarify the molecular mechanisms underlying amikacin resistance in Enterobacteriaceae clinical isolates that do not produce 16S rRNA MTases. Methods PCR was performed to detect already-known amikacin resistance determinants. Cloning experiments and sequence analyses were performed to characterize unknown amikacin resistance determinants. Transfer of amikacin resistance determinants was performed by conjugation and transformation. The complete nucleotide sequence of the plasmids was determined by next-generation sequencing technology. Amikacin resistance enzymes were purified with a column chromatography system. The enzymatic function of the purified protein was investigated by thin-layer chromatography (TLC) and HPLC. Results Among the 14 isolates, 9 were found to carry already-known amikacin resistance determinants such as aac(6′)-Ia and aac(6′)-Ib. Genetic analyses revealed the presence of a new amikacin acetyltransferase gene, named aac(6′)-Ian, located on a 169 829 bp transferable plasmid (p11663) of the Serratia marcescens strain NUBL-11663, one of the five strains negative for known aac(6′) genes by PCR. Plasmid p11663 also carried a novel ESBL gene, named blaTLA-3. HPLC and TLC analyses demonstrated that AAC(6′)-Ian catalysed the transfer of an acetyl group from acetyl coenzyme A onto an amine at the 6′-position of various aminoglycosides. Conclusions We identified aac(6′)-Ian as a novel amikacin resistance determinant together with a new ESBL gene, blaTLA-3, on a transferable plasmid of a S. marcescens clinical isolate.